CEREVIA LTD

Thesis

Cerevia Ltd. is a multifaceted entity with two primary operational focuses: Cerevia Neurosciences and Cerevia.io. Cerevia Neurosciences is dedicated to developing a neuromodulation system for dementia treatment, utilizing image-guided brain stimulation, AI-driven personalization, and non-invasive mobile devices. This division targets healthcare providers, memory care centers, and assisted-living facilities, operating within the Therapeutic Devices industry with verticals in Digital Health, AI & Machine Learning, and HealthTech. Founded in 2025 and headquartered in Rockville, MD, it has received backing from accelerators and incubators, including a $3M grant, indicating an early-stage focus (pre-seed to Series A). Cerevia.io provides AI-powered business tools for B2B customers, with a current focus on a localized chatbot for data privacy. It emphasizes intelligent automation, AI agents, workflow automation, and data intelligence for industries with repetitive workflows, adopting an industry-specific product development strategy. While Cerevia Neurosciences is US-based, Cerevia.io's terms of service suggest a UK presence or operational base. Cerevia Ltd. does not appear to function as a traditional VC firm with a portfolio of external companies; rather, it develops its own technology products and services. Information on AUM, fund size, or typical check sizes for Cerevia as an investment firm is not publicly available.

Related lists

• Pre-seed AI investors
• Pre-seed Enterprise investors
• Pre-seed Healthcare investors